Q3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair
Biodel Inc. (NASDAQ:ALBO) – Research analysts at William Blair decreased their Q3 2017 earnings estimates for shares of Biodel in a research report issued on Monday. William Blair analyst Y. Xu now anticipates that the biopharmaceutical company will earn ($0.79) per share for the quarter, down from their previous forecast of ($0.52). William Blair also issued estimates for Biodel’s Q4 2017 earnings at ($0.86) EPS, FY2017 earnings at ($3.52) EPS, FY2018 earnings at ($2.65) EPS and FY2019 earnings at ($3.48) EPS.
Biodel (NASDAQ:ALBO) last issued its quarterly earnings data on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/23/q3-2017-earnings-forecast-for-biodel-inc-albo-issued-by-william-blair.html.
Several other analysts have also recently commented on ALBO. Zacks Investment Research cut shares of Biodel from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Cowen and Company assumed coverage on shares of Biodel in a research report on Wednesday, August 16th. They issued an “outperform” rating for the company. Needham & Company LLC assumed coverage on shares of Biodel in a research report on Tuesday, July 18th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Wedbush assumed coverage on shares of Biodel in a research report on Friday, June 30th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $31.50.
Shares of Biodel (ALBO) opened at 23.60 on Wednesday. Biodel has a 12 month low of $11.40 and a 12 month high of $37.69. The stock’s market capitalization is $148.49 million. The stock has a 50 day moving average price of $24.50 and a 200 day moving average price of $22.28.
An institutional investor recently raised its position in Biodel stock. Renaissance Technologies LLC boosted its position in Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the period. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.33% of the company’s stock.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.